AU651155B2

AU651155B2 - Aminosulfonyl carbamates

Info

Publication number: AU651155B2
Application number: AU89509/91A
Authority: AU
Inventors: Joseph Armand Picard; Drago Robert Sliskovic
Original assignee: Warner Lambert Co LLC
Current assignee: Warner Lambert Co LLC
Priority date: 1990-11-07
Filing date: 1991-11-05
Publication date: 1994-07-14
Anticipated expiration: 2011-11-05
Also published as: DK0592439T3; DE69133299D1; JP3468738B2; PT99436A; CA2094807A1; US5254715A; DE69133299T2; US5336690A; PT99436B; ATE246171T1; EP0592439B1; EP0592439A1; JP2000319179A; IE913875A1; ES2201048T3; WO1992008693A1; JP3484193B2; AU8950991A; NZ240480A; JPH06501706A

Abstract

A compound of the following general formula which is useful in treating hypercholesterolemia and atherosclerosis: <IMAGE> wherein X is oxygen or sulfur; R is hydrogen, alkyl having from 1 to 8 carbon atoms, or benzyl; R1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, an aralkyl group, a heterocyclic group, or a hydrocarbon chain of from 1 to 20 carbon atoms which is saturated or contains 1 to 3 double bonds and each of R2 and R3 is selected from hydrogen, provided both are not hydrogen, an aralkyl group, a hydrocarbon chain of from 1 to 20 carbon atoms which is saturated or contains 1 to 3 double bonds, an w-substituted alkylC1-6, a heterocyclic group, phenyl, substituted phenyl or NR2R3 taken together form a monocyclic heterocyclic group.

Description

AMINOSULFONYL CARBAMATES

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of copending application Serial Number 07/610,487, filed November 7, 1990. BACKGROUND OF INVENTION

This invention relates to chemical compounds having pharmacological activity, to pharmaceutical compositions which include these compounds, and to a pharmaceutical method of treatment. More

particularly, this invention concerns certain

aminosulfonyl carbamates which inhibit the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT), pharmaceutical compositions containing these

compounds, and a method of treating

hypercholesterolemia and atherosclerosis.

In recent years the role which elevated blood plasma levels of cholesterol plays in pathological conditions in man has received much attention.

Deposits of cholesterol in the vascular system have been indicated as causative of a variety of

pathological conditions including coronary heart disease.

Initially, studies of this problem were directed toward finding therapeutic agents which would be effective in lowering total serum cholesterol levels. It is now known that cholesterol is transported in the blood in the form of complex particles consisting of a core of cholesteryl esters plus triglycerides and an exterior consisting primarily of phospholipids and a variety of types of protein which are recognized by specific receptors. For example, cholesterol is carried to the sites of deposit in blood vessels in the form of low density lipoprotein cholesterol (LDL cholesterol) and away from such sites of deposit by high density lipoprotein cholesterol (HDL

cholesterol).

Following these discoveries, the search for therapeutic agents which are more selective in their action: that is, agents which are effective in

elevating the blood serum levels of HDL cholesterol and/or lowering the levels of LDL cholesterol. While such agents are effective in moderating the levels of serum cholesterol, they have little or no effect on controlling the initial absorption of dietary

cholesterol in the body through the intestinal wall.

In intestinal mucosal cells, dietary cholesterol is absorbed as free cholesterol which must be

esterified by the action of the enzyme acyl- CoA:cholesterol acyltransferase (ACAT) before it can be packaged into the chylomicrons which are then released into the blood stream. Thus, therapeutic agents which effectively inhibit the action of ACAT prevent the intestinal absorption of dietary

cholesterol into the blood stream or the reabsorption of cholesterol which has been previously released into the intestine through the body's own regulatory action.

INFORMATION DISCLOSURE

Phosphorus and Sulfur 19(2), 167-172 (1984) describes the following compounds as fungicides and bactericides.

Ar = 2,6-dimethylphenyl

2,6-dimethoxyphenyl

2,6-diisopropylmethyl

2-methyl-6-isopropylphenyl

2,6-di-tert-butylphenyl

2,6-di-tert-butyl-4-methylphenyl 2,4,6-tri-tert-butylρhenyl

German patent 940,292 dated March 15, 1956 to Farbwerke Hoechst, AG describes the following compounds which are said to be useful as textile assistants, pharmaceuticals and pesticides. No specific pharmaceutical utility is described.

R' R"

C₁₂H₂₅ H

C₂H₅ 4-(OC₂H₅)Ph

C₂H₅ Ph

C₂H₅

^C18^H35

CH₃3 Ph R' R"

C₂H₅ ^C6^H11

ClCH₂CH₂ Ph

ClCH₂CH₂ 4-CH₃-Ph

C₃H₇ C₃H₇

i-C₃H₇ C₆H₁₁

CH₂=CHCH₂- Ph

CH₂=CHCH₂- CH₂CH=CH₂

C₄H₉ Ph

C₄H₉ C₆H₁₁

C₄H₉ H

(Et) ₂CHCH₂2 H

(C₄H₉) (C₂H₅) CHCH₂ H

C₆H₁₁ Ph

Ph-CH₂- C₃H₇

Ph H

4-Cl-Ph -CH₂CH=CH₂

CH₃OCH₂ -CH₂CH=CH₂ Ph-CH₂

C₁₂H₂₅

C₁₈H₃₅ CH₂CH₂NEt₂

Chem. Ber. 96, 56-67(1963) describes compounds of the following formula. No utility for these compounds is disclosed.

R R' R"

CH₃ H Ph

CH₃ H CgHn

C₂H₅ H C-K^

C₂H₅ H Ph

C₂H₅ H 4- (OC₂H₅) -Ph

O

C₂H₅ H 4- (COC₂H₅) Ph

ClCH₂CH₂ CH₃ CH₃

CICH₂CH₂ H 4-CH₃Ph

n-C₃H₇ H n-C₃H₇

i-C₃H₇ H Ph

C₁₂H₂₅ CH₃ CH₃

C₁₈H₃₇ CH₃ CH₃

-CH₂CH=CH₂ H -CH₂CH=CH₂

- CH₂ CH=CH₂ H Ph

C₆H₁₁ CH₃ CH₃

C₆H₁₁ H Ph

Ph CH₃ CH₃

Ph H Ph

Ph H n-C₃H₇

Ph H n-C₄H₉ Ph H

J. Med. Chem. 8., 781-784 (1965) describes the following compounds which are useful as hypoglycemic agents.

Tetrahedron Letters 24, (30) 3091-3094 (1983) describes the following compounds. No use is

described for these compounds.

X R

Cl Ph

Br Ph

Cl -CH₂-Ph

Cl -(C₂H₅)₂

Cl C₆H₁₁

Cl -(CH₂)₄CH₃

SUMMARY OF INVENTION

The present invention provides compounds of the following general Formula I, methods of using said compounds, pharmaceutical compositions and process for preparing the compounds of Formula I

Formula I wherein X is sulfur or oxygen;

wherein R is hydrogen, a straight or branched alkyl having from 1 to 8 carbon atoms, or benzyl;

wherein R₁ is

(a) phenyl which is unsubstituted or is

substituted with from one to three substituents selected from:

phenyl,

alkyl having from one to six carbon atoms and which is straight or branched, alkoxy having from one to six carbon atoms and which is straight or branched, phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-COOalkyl wherein alkyl has from one to four carbon atoms and which is straight or branched,

-(CH₂)_pNR₄R₅ wherein p is zero or one, and each of R₄ and R₅ is hydrogen or a straight or branched alkyl group having one to four carbon atoms;

(b) 1- or 2-naphthyl which is unsubstituted or substituted with one to three substituents selected from

phenyl,

alkyl having from one to six carbon atoms and which is straight or branched, alkoxy having from one to six carbon atoms and which is straight or branched, hydroxy,

phenoxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched,

-(CH₂)_pNR₄R₅ wherein p, R₄, and R₅ have the meanings defined above;

(c) the group

wherein t is zero or one to four; w is zero or one to four with the proviso that the sum of t and w is not greater than five; R₆ and R₇ are independently selected from hydrogen or alkyl having for one to six carbon atoms, or when R₆ is hydrogen, R₇ can be selected from the groups defined for R₈; and R₈ is phenyl or phenyl substituted with from one to three substituents selected from straight or branched alkyl having from one to six carbon atoms, straight or branched alkoxy having from one to six carbon atoms,

phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, -COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or -(CH₂)_pNR₄R₅ wherein p, R₄ and R₅ have the meanings defined above;

(d) -(CH₂)_s-Q wherein s is a number of from zero to three and Q is a 5- or 6-membered monocyclic or fused bicyclic heterocycle containing at least one to four nitrogen, oxygen or sulfur atoms in at least one ring member; or

(e) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;

wherein each of R₂ and R₃ is

(a) hydrogen;

(b) the group

wherein t, w, R₆, R₇ and R₈ have the meanings defined above;

(c) a straight or branched hydrocarbon

chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;

(d) an alkyl group having from one to six carbon atoms wherein the terminal carbon is substituted with hydroxy or -NR₆R₇ wherein R₆ and R₇ have the meanings defined hereinabove;

(e) - (CH₂)_sQ wherein s and Q have the

meanings defined above; (f) phenyl or phenyl substituted with from one to three substituents selected from phenyl,

alkyl having from one to six carbon atoms and which is straight or

branched,

alkoxy having from one to six carbon atoms and which is straight or

branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-COOalkyl wherein the alkyl moiety has from one to four carbon atoms and is straight or branched, or

-(CH₂)_pNR₄R₅ wherein p, R₄, and R₅ have the meanings defined above; or

(g) NR₁R₂ taken together form a monocyclic heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is

unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and

pharmaceutically acceptable salts thereof; with the provisos:

(i) when each of R₂ and R₃ is the group

R₇ is hydrogen or alkyl having from one to six carbon atoms;

(ii) at least one of R₁, R₂, and R₃ is phenyl or substituted phenyl;

(iii) both R₂ and R₃ are not hydrogen at the same time;

(iv) when R₁ is phenyl disubstituted on the

2,6-positions or trisubstituted on the 2,4,6-positions with alkyl having from one to four carbon atoms, or when R₁ is phenyl disubstituted on the

2,6-positions with methoxy, neither of

R₂ or R₃ is phenyl; and

(v) the following compounds wherein Ph

means phenyl are excluded:

R₁ R₂ R₃

C₂H₅ H 4-(OC₂H₅)Ph

C₂H₅ H

C₂H₅ H Ph

CH₃ H Ph

CH₂=CHCH₂ H Ph

C₄H₉ H Ph

Ph-CH₂- H C₃H₇

4 (Cl) -Ph H -CH₂CH=CH₂

i-C₃H₇ H Ph

Ph CH₃ CH₃

Ph H Ph

Ph H n-C₃H₇

Ph H n-C₄H₉

Ph H

The present invention also provides

pharmaceutical compositions containing compounds of the following general Formula II and the method of treating hypercholesterolemia and atherosclerosis using the compounds of the following Formula II:

Formula II wherein X is sulfur or oxygen; wherein R is hydrogen, a straight or branched alkyl having from 1 to 8 carbon atoms, or benzyl;

wherein R₁ is

(a) phenyl which is unsubstituted or is

substituted with from one to three substituents selected from:

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

phenyl,

phenoxy,

fluorine,

chlorine,

bromine,

nitro, trifluoromethyl,

-COOH,

-COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, -(CH₂)_pNR₄R₅ wherein p, R₄, and R₅ have the meanings defined above;

(c) the group

phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, -COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or

-(CH₂)_pNR₄R₅ wherein p, R₄ and R₅ have the meanings defined above;

wherein each of R₂ and R₃ is

(a) hydrogen;

(b) the group

wherein t, w, R₆, R₇ and R₈ have the meanings defined above;

(c) a straight or branched hydrocarbon

(d) an alkyl group having from one to six carbon atoms wherein the terminal carbon is substituted with hydroxy or

-NR₆R₇ wherein R₆ and R₇ have the meanings defined hereinabove;

(e) -(CH₂)_sQ wherein s and Q have the

meanings defined above;

(f) phenyl or phenyl substituted with from one to three substituents selected from phenyl,

alkyl having from one to six carbon atoms and which is straight or branched, alkoxy having from one to six carbon atoms and which is straight or

branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

pharmaceutically acceptable salts thereof; with the provisos:

(i) when each of R₂ and R₃ is the group

R₇ is hydrogen or alkyl having from one to six carbon atoms; (ii) at least one of R₁, R₂, and R₃ is phenyl or substituted phenyl;

(iii) both R₂ and R₃ are not hydrogen at the same time.

DETAILED DESCRIPTION OF INVENTION

The compounds of the present invention provide a novel class of aminosulfonyl carbamates which are ACAT inhibitors rendering them useful in treating

hypercholesterolemia and atherosclerosis.

Illustrative examples of straight or branched saturated hydrocarbon chains having from 1 to 20 carbon atoms include methyl, ethyl, n-propyl,

isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n,-heptyl, n-octyl, n-undecyl, n-dodecyl, n-hexadecyl, 2,2-dimethyldodecyl,

2-tetradecyl, and n-octadecyl groups.

Illustrative examples of straight or branched hydrocarbon chains having from 1 to 20 carbon atoms and having from 1 to 3 double bonds include ethenyl, 2-propenyl, 2-butenyl, 3-pentenyl, 2-octenyl,

5-nonenyl, 4-undecenyl, 5-heptadecenyl, 3-octadecenyl, 9-octadecenyl, 2, 2-dimethyl-11-eicosenyl,

9,12-octadecadienyl, and hexadecenyl.

Straight or branched alkoxy groups having one to six carbon atoms include, for example, methoxy, ethoxy, n-propoxy, t-butoxy, and pentyloxy.

Straight or branched alkyl groups having from one to six carbon atoms include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl,

n-hexyl, and tert-butyl.

A 5- or 6-membered monocyclic or fused bicyclic heterocycle is a monocyclic or fused bicyclic aromatic ring containing at least one to four heteroatoms in at least one ring, such as nitrogen, oxygen, or sulfur or a combination thereof. Such a heterocyclic group includes, for example, thienyl, benzothienyl, furanyl, benzofuranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, pyrazolyl, isothiazolyl,

thiazolyl, oxazolyl, isoxazolyl, triazolyl,

tetrazolyl, imidazolyl, benzothiazolyl, indolyl, quinolinyl, isoquinolinyl, or N-oxides of heterocycle containing a nitrogen atom.

More specifically, such a heterocycle may be a 2- or 3-thienyl; 2- or 3-furanyl; 2-, or 3-, or 4-pyridyl or 2-, or 3-, or 4-pyridyl-N-oxide; 2-, 4-, or

5-pyrimidinyl; 3- or 4-pyridazinyl; 2-pyrazinyl;

2-pyrazinyl-N-oxide; 2- or 3-pyrrolyl; 3-, 4-, or 5-pyrazolyl; 2-, 4-, or 5-thiazolyl; 3-, 4-, or

5-isoxazolyl; 2-, 4-, or 5-oxazolyl; 3-, 4-, or

5-isothiazolyl; 5-tetrazolyl; 3- or

5-(1,2,4,-)triazolyl; 4- or 5- (1,2,3-)triazolyl; 2-, 4-, or 5-imidazolyl; 2-, 3-, 4-, 5-, 6-, or 7-indolyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl; 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl; 2-, 4-, 5-, 6-, or 7-benzothiazolyl; or 2-, 3-, 4-, 5-, 6-, or

7-benzothienyl.

Preferred compounds of general Formulas I and II are those wherein one of R₁, R₂, and R₃ is phenyl disubstituted in the 2, 6-positions. More preferably R₁ and R₂ are 2, 6-disubstituted phenyl and R₃ is hydrogen. Compounds wherein R₁ is 2, 6-disubstituted phenyl and R₂ and R₃ are a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms, and more preferably, 6 to 18 carbon atoms, and which is saturated or contains from 1 to 3 double bonds are also preferred. Pharmaceutically acceptable salts of the

compounds of Formula I are also included as a part of the present invention.

The base salts may be generated from compounds of Formula I and Formula II by reaction of the latter with one equivalent of a suitable nontoxic,

pharmaceutically acceptable base followed by

evaporation of the solvent employed for the reaction and recrystallization of the salt, if required. The compounds of Formula I may be recovered from the base salt by reaction of the salt with an aqueous solution of a suitable acid such as hydrobromic, hydrochloric, or acetic acid, or by reaction with a suitable

alkylating agent such as an alkyl halide, e.g., methyl iodide or benzyl bromide.

Suitable bases for forming base salts of the compounds of this invention include amines such as triethylamine or dibutylamine, or alkali metal bases and alkaline earth metal bases. Preferred alkali metal hydroxides and alkaline earth metal hydroxides as salt formers are the hydroxides of lithium, sodium, potassium, or calcium. The class of bases suitable for the formation of nontoxic, pharmaceutically acceptable salts is well known to practitioners of the pharmaceutical formulation arts. See, for example, Stephen N. Berge, et al, J Pharm Sciences 66:1-19 (1977).

Suitable acids for forming acid salts of the compounds of Formulas I and II containing a basic group include, but are not necessarily limited to acetic, benzoic, benzenesulfonic, tartaric,

hydrobromic, hydrochloric, citric, fumaric, gluconic, glucuronic, glutamic, lactic, malic, maleic,

methanesulfonic, pamoic, salicylic, stearic, succinic, sulfuric, and tartaric acids. The acid addition salts are formed by procedures well known in the art.

Certain compounds of the present invention may also exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compound. The present invention contemplates all stereoisomers may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers in chiral chromatographic columns.

Further, the compounds of this invention may exist in unsolvated as well as solvated forms wth pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

As shown by the data presented below in Table 1, the compounds of the present invention are potent inhibitors of the enzyme acyl-CoA: cholesterol

acyltransferase (ACAT), and are thus effective in inhibiting the esterification and transport of

cholesterol across the intestinal cell wall. The compounds of the present invention are thus useful in pharmaceutical formulations for the treatment of hypercholesterolemia or atherosclerosis.

The ability of representative compounds of the present invention to inhibit ACAT was measured using an in vitro test more fully described in F. J. Field and R. G. Salone, Biochemica et Biophysica 712:557-570 (1982). The test assesses the ability of a test compound to inhibit the acylation of cholesterol by oleic acid by measuring the amount of radiolabeled cholesterol oleate formed from radiolabeled oleic acid in a tissue preparation containing rabbit intestinal microsomes. The data appear in Table 1 where they are expressed as IC₅₀ values; i. e,., the concentration of test compound required to inhibit the activity of the enzyme by 50%.

TABLE 1

IAI

Example No. IC₅₀

(μM)

1 >100 2 33 3 82 4 15 5 11.4 6 16.8 7 21.8 8 19 9 11

10 58 11 1.9 12 20 13 52 14 38 15 49 16 25.8 17 10.6 18 11.5 19 13.5 20 24.4 21 23.4 22 3.2 23 2.2 24 3.2 25 4.3 26 19.4 27 18.9 28 164 29 18 TABLE 1

IAI

Example No. IC₅₀

(μM)

30 21

31 2.7

32 31

33 31

34 89

35 15

36 12

37 21

38 58

39 5.1

40 22

41 4.2

42 1.3

43 30.0

50 >100

51 >100

52 53

53 >100

54 43

56 >25

57 1.9

58 4.6 In one in vivo screen designated APCC, male

Sprague-Dawley rats (200 to 225 g) were randomly divided into treatment groups and dosed at 4 PM with either vehicle (CMC/Tween) or suspensions of compounds in vehicle. The normal chow diet was then replaced with a high fat, high cholesterol diet with 0.5% cholic acid. The rats consumed this diet ad libitum during the night and were sacrificed at 8 AM to obtain blood samples for cholesterol analysis using standard procedures. Statistical differences between mean cholesterol values for the same vehicle were

determined using analysis of variance followed by Fisher's least significant test. The results of this trial for representative compounds of the present invention appear in Table 2. The compounds were dosed at 30 mg/kg unless otherwise noted.

TABLE 2

Compound of Example % Change (mg/dl)

1 - - -

2 0

3 -55

4 -77

5* -35

6* -57

7* -32

8* -26

9* -3

10 -67

11 -57

12 -43

13 +8

14* -55

15* -29

16* -65

17* -46

18* -42

19* -56

20* -54

21* -33

22 -4

23 -42

24 -19

25 -40

26 -52

27 -29 TABLE 2

Compound of Example % Change (mg/dl)

29 -55

30 +2

31 0

32 -10

33 -22

34 -4

35 -76

36 -70

37 -58

38 -70

39 -60

40 -60

41 -62

42 -74

43 -8

50 -14

51 -11

52 -53

53 -21

54 -77

56 -39

57 -66

58 +4

* Indicates dosed at 50 mg/kg

In therapeutic use as agents for treating

hypercholesterolemia or atherosclerosis, the compounds of Formula I or pharmaceutically acceptable salts thereof are administered to the patient at dosage levels of from 250 to 3000 mg per day. For a normal human adult of approximately 70 kg of body weight, this translates into a dosage of from 5 to 40 mg/kg of body weight per day. The specific dosages employed, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is within the skill of the art. For preparing the pharmaceutical compositions from the compounds of this invention, inert,

pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, and cachets.

A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding

properties in suitable proportions and compacted in the shape and size desired.

Powders and tablets preferably contain between about 5% to about 70% by weight of the active

ingredient. Suitable carriers are magnesium

dicarbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner cachets are also included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral

administration. Liquid form preparations include solutions, suspensions, or emulsions suitable for oral

administration. Aqueous solutions for oral

administration can be prepared by dissolving the active compound in water and adding suitable

flavorants, coloring agents, stabilizers, and

thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethylcellulose, and other suspending agents known to the pharmaceutical formulation art.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate

quantities of the active component. The unit dosage form can be a packaged preparation containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.

The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of these packaged forms.

The compounds of general Formulas I and II are prepared as generally described in Chart I hereof.

An alcohol or thiol of the formula R₁XH is reacted with chlorosulfonyl isocyanate in an inert organic solvent such as THF, Et₂O, CH₂Cl₂ at room temperature or preferably colder (≤0°C). The

resulting chlorosulfonyl (thio) carbamate may

precipitate out of solution or it can be triturated with a non polar solvent such as hexanes. The

chlorosulfonyl (thio) carbamate can be isolated or it can be used as is and reacted with an amine of the formula NHR₂R₃ in an inert organic solvent such as those mentioned above at ambient temperature in the presence of an acid scavenger such as triethylamine. The oxysulfonyl (thio) carbamate thus formed can be converted to its base salt by reacting with an

appropriate metal or amine base. The base salt can then be reacted with an appropriate alkylating agent such as methyl iodide or benzyl bromide.

The alcohols R₁OH, thiols, R₁SH, and amines NHR₂R₃ used in preparing the compounds of this invention are known in the art or are prepared by procedures

generally known in the art.

The specific examples set forth below further illustrate the preparation of compounds of general Formula I and Formula II.

EXAMPLE 1

Methyl[[2,6-bis(1-methylethyl)phenylamino]sulfonyl] carbamate

A solution of methyl (chlorosulfonyl) carbamate (5.0 g, 28.8 mmol) in 60 mL THF was added dropwise to a solution of 2, 6-diisopropylaniline (5.11 g,

28.8 mmol) and excess triethylamine (~5 mL) in 100 mL THF at room temperature under an atmosphere of N₂. The mixture was stirred for 72 hrs, concentrated in vacuo and the residue was partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO₄, filtered and evaporated to give an orange oil which was triturated with 10% EtOAc/hexanes to give 5.93 g (65%) of an off-white solid, mp 152-155°C.

EXAMPLE 2

Dodecyl[ [2 ,6-bis(1-methylethyl)phenyl]amino]sulfonyl] carbamate

A solution of dodecyl (chlorosulfonyl) carbamate (5.0 g, 15.2 mmol) in 70 mL THF was added dropwise to a solution of 2,6-diisopropylaniline (2.70 g,

15.2 mmol) and excess triethylamine (~5 mL) in 100 mL THF at room temperature under an atmosphere of N₂.

The mixture was stirred for 16 hrs, concentrated in vacuo and partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO₄, filtered and concentrated to give an orange oil. Chromatography (SiO₂, 5% EtOAc/hex) gave 5.86 g (82%) of an off-white solid, mp 82-84°C (hexanes).

EXAMPLE 3

2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl[[(2,2-diphenylethyl)amino]sulfonyl]carbamate

A solution of 2, 6-bis (1,1-dimethylethyl)-4- methoxyphenyl (chlorosulfonyl) carbamate (5.0 g,

13.2 mmol) in 80 mL THF was added dropwise to a solution of 2,2-diphenylethylamine (2.61 g, 13.2 mmol) and excess triethylamine (~3 mL) in 100 mL THF at room temperature under an atmosphere of N₂. The mixture was stirred for 72 hrs and then concentrated in vacuo. The residue was partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO₄, filtered and evaporated to give a clear oil which was triturated with hexanes to give 5.36 g (75%) of an off-white solid, mp 132-138°C.

EXAMPLE 4

2,6-bis(1,1-dimethylethyl)-4-methoxy phenyl[[ 2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate

When in the general procedure of Example 3, an appropriate amount of 2, 6-diisopropylaniline was substituted for 2,2-diphenylethylamine, the title compound was obtained, mp 155-158°C. EXAMPLE 5

2,6-bis(1,1-dimethylethyl)phenyl[[(diphenylmethyl)-amino] sulfonyl] carbamate

A solution of 2,6-bis(1,1-dimethylethyl) phenyl (chlorosulfonyl) carbamate (2.85 g, 8.2 mmol) in 70 mL Et₂O was added dropwise to a solution of

diphenylmethylamine (1.50 g, 8.2 mmol) and

triethylamine (1.25 mL, 9.0 mmol) in 80 mL Et₂O at -15°C under an atmosphere of N₂. The mixture was warmed to room temperature and stirred for 6 hrs and then washed with 1N HCl and water. The organic layer was dried with MgSO₄, filtered and evaporated to give 3.60 g (89%) of an off-white solid, mp 162-166°C. EXAMPLE 6

2,6-bis(1,1-dimethylethyl)phenyl[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate

When in the general procedure of Example 5, an appropriate amount of 2,6-diisopropylaniline was substituted for diphenylmethylamine, the title

compound was obtained, mp 180-181°C.

EXAMPLE 7

2,6-bis(1,1-dimethylethyl)phenyl[ [ (2 ,2-diphenylethyl)- amino]sulfonyl]carbamate

When in the general procedure of Example 5, an appropriate amount of 2,2-diphenylethylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 147-150°C.

EXAMPLE 8

2,6-bis(1,1-dimethylethyl)phenyl[(phenylamino)- sulfonyl]carbamate

When in general procedure of Example 5, an appropriate amount of aniline was substituted for diphenylmethylamine, the title compound was obtained, mp 169-172°C.

EXAMPLE 9

2 ,6-bis(1,1-dimethylethyl)phenyl[[bis(phenylmethyl)amino]sulfonylcarbamate

When in general procedure of Example 5, an appropriate amount of dibenzylamine was substituted for diphenylamine, the title compound was obtained, mp 182-183°C.

EXAMPLE 10

2,6-bis(1-methylethyl)phenyl[(diphenylamino)-sulfonyl]carbamate

Solid NaH (0.68 g, 17.1 mmol) was added in portions to a solution of diphenylamine (2.41 g,

14.2 mmol) in 75 mL THF at room temperature under an atmosphere of N₂. The mixture was stirred for 16 hrs and then a solution of 2,6-bis(1-methylethyl) phenyl (chlorosulfonyl) carbamate (5.0 g, 15.6 mmol) in 50 mL THF was added dropwise. The reaction mixture was stirred for an additional 4 hrs and then quenched with 10 mL 1N HCl, and partitioned between 1N HCl and

EtOAc. The organic layer was dried with MgSO₄, filtered, and evaporated to give a green oil which was triturated and recrystallized from hexane to give 3.21 g (50%) of the title compound as an off-white solid, mp 149-151°C. EXAMPLE 11

Synthesis of 2 , 6-Bis (1-methylethyl) phenyl[(dibutylamino)sulfonyl]carbamate

A solution of 2,6-bis(1-methylethyl)phenyl- (chlorosulfonyl) carbamate (5.0 g, 15.66 mmoles) in 75 mL THF was added dropwise to a solution of di-n-butylamine (1.84 g, 14.2 mmoles) and excess triethylamine (~2 mL) in 75 mL THF. This was then stirred for 16 hours and then partitioned between 1N HCl and EtOAc. The organic layer was dried with

MgSO₄, filtered, and evaporated to give a pale orange oil. Chromatography (SiO₂, 5% EtOAc/hexane) gave 1.64 g (25%) of the title compound as a white solid, mp 94-97°C. EXAMPLE 12

Synthesis of 2 ,6-Bis(1-methylethyl)phenyl[[bis(phenylmethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of dibenzylamine was substituted for di-n-butylamine, the title compound was obtained, mp 143-146°C.

EXAMPLE 13

Synthesis of 2,6-Bis(1-methylethyl)phenyl[(1H- benzimidazol-2-ylamino)sulfonyl]carbamate

When in.the general procedure of Example 11, an appropriate amount of 2-aminobenzimidazole was substituted for di-n-butylamine, the title compound was obtained, mp 159-162°C.

EXAMPLE 14

Synthesis of 2 ,6-Bis(1-methylethyl)phenyl[(phenylamino)sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of aniline was substituted for di-n-butylamine, the title compound was obtained, mp 165-168°C. EXAMPLE 15

Synthesis of 2,6-Bis(1-methylethyl)phenyl[[2,2-diphenylethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of 2,2-diphenylethylamine was substituted for di-n-butylamine, the title compound was obtained, mp 103-105°C.

EXAMPLE 16

Synthesis of 2,6-Bis(1-methylethyl)phenyl

methylethyl)phenyl]amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of 2,6-diisopropylaniline was substituted for di-n-butylamine, the title compound was obtained, mp 172-174°C.

EXAMPLE 17

Synthesis of 2,6-Bis(1-methylethyl)phenyl[ [(diphenylmethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of diphenylmethylamine was

substituted for di-n-butylamine, the title compound was obtained, mp 185-187°C. EXAMPLE 18

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[ [(diphenylmethyl)amino]sulfonyl]carbamate

A solution of 2,6-bis(1,1-dimethylethyl)-4-methylphenyl(chlorosulfonyl)carbamate (2.96 g,

8.2 mmoles) in 70 mL Et₂O was added dropwise to a solution of diphenylmethylamine (1.5 g, 8.2 mmoles) and 1.25 mL (10.0 mmoles) of triethylamine in 80 mL Et₂O at -15°C under an atmosphere of N₂. The mixture was allowed to warm to room temperature over 2 hours and then washed with 1N HCl and H₂O. The Et₂O layer was dried with MgSO₄, filtered, and evaporated to give a pale yellow foam which was triturated with hexanes to give a white solid, mp 150-152°C. EXAMPLE 19

Synthesis of 2 ,6-Bis(1,1-dimethylethyl)-4-methylphenyl[ [[bis(2,6-bis(1-methylethyl)phenyl]amino]-sulfonyl]carbamate

When in the procedure of Example 18, an

appropriate amount of 2,6-diisopropylaniline was substituted for diphenylmethylamine, the title

compound was obtained, mp 176-178°C.

EXAMPLE 20

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[(2,2-diphenylethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of 2,2-diphenylethylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 139-141°C.

EXAMPLE 21

Synthesis of 2,6-Bis(1-1-dimethylethyl)-4-methylphenyl[(phenylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of aniline was substituted for diphenylmethylamine, the title compound was obtained, mp 186-188°C. EXAMPLE 22

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dibutylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of di-n-butylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 134-135°C.

EXAMPLE 23

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dipentylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of di-n-pentylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 107-108°C.

EXAMPLE 24

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[bis(1-methylethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of diisopropylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 198-199°C. EXAMPLE 25

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dihexylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of di-n-hexylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 66-68°C.

EXAMPLE 26

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(hexylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of hexylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 123-128°C. EXAMPLE 27

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[methyl(2-phenylethyl)amino]sulfonyl]carbamate When in the general procedure of Example 18, an appropriate amount of N-methyl-2-phenylethylamine was substituted for diphenylmethylamine, the title

compound was obtained, mp 140-142°C.

EXAMPLE 28

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[bis-3-(di-methylamino)propyl]amino]sulfonyl]-carbamate

When in the general procedure of Example 18, an appropriate amount of bis-3-(dimethylamino)propyl amine was substituted for diphenylmethylamine, the title compound was obtained. ¹H NMR (CDCl₃) δ 8.05 (bs, 1H), 7.05 (s, 2H), 3.29 (m, 4H), 2.87 (m, 4H), 2.56 (s, 12H), 2.29 (s, 3H), 1.91 (m, 4H), 1.37 (s, 18H) ppm.

EXAMPLE 29

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(methyl octyl amino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of N-methyl octylamine was

substituted for diphenylmethylamine, the title compound was obtained, mp 65-68°C.

EXAMPLE 30

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methyl- [[bis[(tetrahydro-2-furanyl)methyl]amino]sulfonyl] carbamate

When in the general procedure of Example 18, an appropriate amount of bis-[(tetrahydro-2-furanyl)- methyl]amine was substituted for diphenylmethylamine, the title compound was obtained, mp 108-111°C.

EXAMPLE 31

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dioctylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of di-n-octylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 53-55°C.

EXAMPLE 32

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]-sulfonyl]carbamate, hydrochloride salt

A solution of 2,6-bis(1,1-dimethylethyl)-4-methylphenyl(chlorosulfonyl) carbamate (5.0 g,

13.8 mmoles) in 70 mL THF was added dropwise to a solution of 2-(ß-methylaminoethyl)pyridine (1.88 g, 13.8 mmoles) and excess triethylamine (~2 mL) in 80 mL THF at room. temperature under an atmosphere of N₂. The solution was stirred for 16 hours and then

concentrated in vacuo. The residue was partitioned between 1N HCl and EtOAc, the EtOAc layer dried with MgSO₄, filtered, and evaporated to give a white solid which was then triturated with hexanes to give 5.00 g of the title compound, mp 178-181°C.

EXAMPLE 33

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]sulfonyl]-carbamate, sodium salt

Excess 1N NaOH (30 mL) was added to a suspension of 2,6-bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl2-(2-pyridinyl)ethyl]amino]sulfonyl]carbamate hydrochloride (2.75 g, 5.5 mmoles) in 50 mL EtOAc.

The mixture was stirred for 16 hours, the organic layer separated, dried with MgSO₄, filtered, and evaporated to give a clear oil which was triturated with hexanes to give the title compound as a white solid, mp 133-136°C.

EXAMPLE 34

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dodecylamino)sulfonyl]carbamate

When in the general procedure of Example 18, an appropriate amount of di-n-decylamine was substituted for diphenylmethylamine, the title compound was obtained as a waxy white solid, mp 63-65°C.

EXAMPLE 35

Synthesis of 2,6-Bis(1-methylethyl)phenyl[[bis(1- methylethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of diisopropylamine was substituted for di-n-butylamine, the title compound was obtained, mp 126-131°C.

EXAMPLE 36

Synthesis of 2,6-Bis(1-methylethyl)phenyl[[(1- methylethyl)phenylmethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of N-isopropyl benzylamine was substituted for di-n-butylamine, the title compound was obtained, mp 156-159°C. EXAMPLE 37

Synthesis of 2,6-Bis(1-methylethyl)phenyl[(hexylamino)sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of n-hexylamine was substituted for di-n-butylamine, the title compound was obtained, mp 105-106.5°C.

EXAMPLE 38

Synthesis of 2,6-Bis(1-methylethyl)phenyl[(dioctylamino)sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of di-n-octylamine was substituted for di-n-butylamine, the title compound was obtained, mp 64-67°C.

EXAMPLE 39

Synthesis of 2 ,6-Bis(1-methylethyl)phenyl[[cyclohexyl(1-methylethyl)amino]sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of N-isopropylcyclohexylamine was substituted for di-n-butylamine, the title compound was obtained, mp 133-135°C. EXAMPLE 40

Synthesis of 2,6-Bis(1-methylethyl)phenyl[(methyloctylamino)sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of N-methyloctylamine was

substituted for di-n-butylamine, the title compound was obtained, mp 32-35°C. EXAMPLE 41

Synthesis of 2,6-Bis(1-methylethyl)phenyl[(dihexylamino)sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of di-n-hexylamine was substituted for di-n-butylamine, the title compound was obtained, mp 57-61°C.

EXAMPLE 42

Synthesis of 2 ,6-Bis(1-methylethyl)phenyl[(dipentylamino)sulfonyl]carbamate

When in the general procedure of Example 11, an appropriate amount of di-n-pentylamine was substituted for di-n-butylamine, the title compound was obtained, mp 69-70°C.

EXAMPLE 43

Synthesis of Dodecyl[[(2,4,6-trimethoxyphenyl)amino]- sulfonyl]carbamate

When in the general procedure of Example 2, an appropriate amount of 2,4,6-trimethoxyaniline was substituted for 2,6-diisopropylaniline, the title compound was obtained, mp 133-136°C. The following Example 44 through 49 teach the preparation of intermediates useful in preparing final products of the present invention.

EXAMPLE 44

Synthesis of Methyl(chlorosulfonyl)carbamate (Ref: Org. Synth. 56 40 (1977))

A solution of methanol (10.2 mL, 252 mmoles) in 15 mL toluene was added dropwise to a solution of chlorosulfonyl isocyanate (22.0 mL, 252 mmoles) in 75 mL toluene at 0°C. The cooling bath was removed and stirred for one-half hour at room temperature. This was then cooled to 0°C and 65 mL ice cold hexanes was added. The white precipitate was collected by filtration and washed 2 times with a small amount of cold hexane to give 33.0 g of a white solid,

mp 72-74°C.

EXAMPLE 45

Synthesis of Dodecyl(chlorosulfonyl)carbamate (Ref: R. Graf, Chem. Ber. 96 56 (1963))

A solution of n-dodecyl alcohol (107 g,

52.4 mmoles) in 100 mL Et₂O was added dropwise to a solution of chlorosulfonyl isocyanate (5.0 mL,

57.4 mmoles) in 100 mL Et₂O at -15°C under an

atmosphere of N₂. The resulting mixture was stirred for 2 hours and concentrated in vacuo. The residue was triturated with cold hexanes to give a white solid which was collected by filtration to give 19.12 g of a white solid, mp 62-63°C.

EXAMPLE 46

Synthesis of 2,6-Bis(1-methylethyl)phenyl(chlorosulfonyl)carbamate (Ref: Phos & Sulf 19.167 (1984)) A solution of 2, 6-diisopropylphenol (37.1 mL, 0.2 moles) in 200 mL Et₂O was added dropwise to a solution of chlorosulfonyl isocyanate (17.4 mL,

0.2 moles)) in 200 mL Et₂O at -15°C. This was then stored at -15°C under an atmosphere of N₂ for

16 hours. Concentration gave an orange oil which was triturated with hexanes and quickly collected by filtration to give 55.64 g (87%) of product as a white solid. EXAMPLE 47

Synthesis of 2,6-Bis(1,1-dimethylethyl)phenyl(chlorosulfonyl)carbamate (Ref: Phos & Sulf 19 167 (1984)) A solution of 2,6-di-t-butylphenol (20.63 g, 0.1 mol) in 100 mL Et₂O was added dropwise to a

solution of chlorosulfonyl isocyanate (8.7 mL,

0.1 moles) in 100 mL Et₂O at -15°C (acetone/ice bath) under an atmosphere of N₂. This was stirred for

1 hour and then concentrated in vacuo to leave a thick gel which was triturated with hexanes and filtered to give 28.60 g (82%) of the title compound as a white solid, mp 135-137°C.

EXAMPLE 48

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl(chlorosulfonyl)carbamate (Ref: Phos & Sulf 19. 167 (1984))

A solution of 2,6-di-t-butyl-4-methylphenol

(22.04 g, 0.1 moles) in 100 mL Et₂O was added dropwise to a solution of chlorosulfonyl isocyanate (8.7 mL,

0.1 moles) in 100 mL Et₂O at -15°C under an atmosphere of N₂. This was stirred for 2 hours, concentrated and trituration of the resulting gel with hexanes gave 26.82 g (74%) of the title compound as a white solid.

EXAMPLE 49

Synthesis of 2,6-Bis(1,1-dimethylethyl)-4-methoxyphenyl(chlorosulfonyl)carbamate

A solution of 3,5-di-t-butyl-4-hydroxyanisole (30.0 g, 0.127 moles) in 200 mL Et₂O was added

dropwise to a solution of chlorosulfonyl isocyanate (12.2 mL, 0.14 moles) in 250 mL Et₂O at -15°C under an atmosphere of N₂. This was stirred for 1 hour and then concentrated in vacup to give 41.0 g of product as a thick gel which was used without further

purification.

The examples set forth hereinbelow further illustrate the preparation of final products of the compounds of the present invention.

When in the procedure of Example 11 an

appropriate amount of the amine listed below was substituted for di-n-butylamine the respective product listed below was obtained:

Example Amine Product

No.

50 Morpholine 2, 6-Bis (1-methylethyl)- phenyl ester (4- morpholinylsulfonyl)- carbamic acid;

1H NMR (CDCl₃) δ 7 .9

(bs, 1H), 7.1 (m, 3H), 3.7 (t, 4H), 3.5 (5, 4H), 3.0 (m, 2H), 1.2

(d, 12H) ppm.

51 Piperidine 2, 6-Bis (1-methylethyl)- phenyl ester (1- piperidinylsulfonyl)- carbamic acid;

1H NMR (CDCl₃) δ 8.1

(bs, 1H), 7.1 (m, 3H),

3.4 (t, 4H), 3.0 (m,

2H), 1.7 (m, 4H), 1.6

(m, 2H), 1.2 (d,

12H) ppm

52 Pyrrolidine 2,6-Bis (1-methylethyl)- phenyl ester (1- pyrrolidinylsulfonyl)- carbamic acid;

1H NMR (CDCl₃) δ 7.8

(bs, 1H), 7.1 (m, 3H),

3.6 (t, 4H), 3.0 (m,

2H), 1.9 (t, 4H), 1.2

(d, 12H) ppm.

53 4-Methylpipera2,6-Bis (1-methylethyl)- zine phenyl ester,

monohydrochloride[(4- methyl-1-piperazinyl)- sulfonyl]carbamic acid; 1H NMR (DMSO D₆) δ 8.0 (S, 1H), 7.0 (d, 3H),

3.3 (m, 2H), 3.1 (bs,

4H), 2.8 (bs, 4H), 2.5 (s, 3H), 1.1 (d,

12H) ppm.

54 2,3-Dihydroindole 2,6-Bis (1-methylethyl)- phenyl ester [(2,3- dihydro-1H-indol-1- yl)sulfonyl [carbamic acid; ¹H NMR (CDCl₃) δ

8.0 (bs, 1H), 7.4 (d, 1H), 7.2 (m, 3H), 7.1 (m, 3H), 4.4 (t, 2H),

3.1 (t, 2H), 2.5 (m, 2H), 1.0 (d, 12H) ppm. EXAMPLE 55

Synthesis of [1,1':3',1"-terphenyl]-2'-yl(chlorosulfonyl) carbamate

A solution of 2,6-diphenyl phenol (25.0 g,

101 mmol) in 250 mL ethyl ether was added dropwise to a solution of chlorosulfonyl isocyanate (9.7 mL, 112 μmol) in 100 mL hexane at -15°C under an

atmosphere of nitrogen. The resulting white

suspension was allowed to warm to room temperature over 2 hours. Concentrated in vacuo and triturated with ice cold hexane. Vacuum filtration afforded the title compound as a white solid, mp 159-162°C.

EXAMPLE 56

Synthesis of [1,1':3',1"-terphenyl]-2 '-yl[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate

A solution of [1,1':3',1"-terphenyl]-2'-yl(chlorosulfonyl)carbamate (5.0 g, 12.9 mmol) in 75 mL tetrahydrofuran was added dropwise to a solution of 2,6-diisopropyl aniline (2.29 g, 12.9 mmol) and triethylamine (1.3 g, 12.9 mmol) in 100 mL

tetrahydrofuran at -15°C under an atmosphere of nitrogen. The resulting mixture was warmed to room temperature and stirred for 16 hours. Concentrated in vacuo and partitioned the residue between water and ethyl acetate. Dried the organic layer over MgSO₄ and evaporated to give an off-white solid. Chromatography on silica gel gave the title compound, mp 166-168°C. EXAMPLE 57

Synthesis of 2,6-bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate monosodium salt

A solution of the 2, 6-bis (1-methylethyl)phenyl-[(dibutylamino)sulfonyl]carbamate (5.5 g, 13.3 mmol) in 75 mL tetrahydrofuran was added dropwise to a suspension of sodium hydride (0.4 g, 80% dispersion in mineral oil, 13.3 mmol) in 50 mL tetrahydrofuran at 0°C under an atmosphere of nitrogen. Stirred for 3 hours, gradually warming to room temperature.

Concentrated in vacuo and triturated with hexanes to give the title compound, mp 162-166°C.

EXAMPLE 58

Synthesis of 2, 6-bis(1,1-dimethylethyl)phenyl- [[(diphenylmethyl)amino]sulfonyl]methyl carbamate

1,8-Diazabicyclo[5.4.0]undec-7-ene (1.0 mL,

6.7 mmol) was added in one portion to a solution of 2, 6-bis (1,1-dimethylethyl)phenyl[[(diphenylmethyl)-amino]sulfonyl]carbamate (3.0 g, 6.1 mmol) and methyl iodide (0.95 g, 6.7 mmol) in 50 mL acetonitrile at room temperature and the resulting mixture was stirred for 16 hours. Partitioned between 1N HCl and ethyl acetate. Dried the organic layer over MgSO₄,

filtered, and evaporated to give an orange oil.

Chromatography on silica gel gave the title compound, mp 175-178°C.

Claims

1. A compound of the formula

wherein R is hydrogen, a straight or branched alkyl group having from 1 to 8 carbon atoms, or benzyl;

wherein R₁ is

(a) phenyl which is unsubstituted or is

substituted with from one to three substituents selected from:

phenyl,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

phenyl,

alkyl having from one to six carbon atoms and which is straight or branched,

alkoxy having from one to six carbon atoms and which is straight or branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-(CH₂)_pNR₄R₅ wherein p, R₄, and R₅ have the meanings defined above;

(c) the group

(d) -(CH₂)_s-Q wherein s is a number of from zero to three and Q is a 5- or 6-membered

monocyclic or fused bicyclic heterocycle containing at least one to four nitrogen, oxygen or sulfur atoms in at least one ring member; or

wherein each of R₂ and R₃ is

(a) hydrogen;

(b) the group

wherein t, w, R₆, R₇ and R₈ have the meanings defined above;

(c) a straight or branched hydrocarbon

-NR₆R₇ wherein R₆ and R₇ have the meanings defined hereinabove;

(e) -(CH₂)_sQ wherein s and Q have the

meanings defined above;

alkyl having from one to six carbon atoms and which is straight or

branched,

alkoxy having from one to six carbon atoms and which is straight or

branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

(g) NR₁R₂ taken together form a monocyclic heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and

pharmaceutically acceptable salts thereof; with the provisos:

(i) when each of R₂ and R₃ is the group

R₇ is hydrogen or alkyl having from one to six carbon atoms;

(ii) at least one of R₁, R₂, and R₃ is phenyl or substituted phenyl;

(iii) both R₂ and R₃ are not hydrogen at the same time;

(iv) when R₁ is phenyl disubstituted on the 2, 6-positions with alkyl having from one to four carbon atoms or with methoxy, or trisubstituted on the 2,4, 6-positions with alkyl having from one to four carbon atoms, neither of R₂ or R₃ is phenyl; and

(v) the following compounds wherein Ph

means phenyl are excluded:

R₁ R₂ R₃

C₂H₅ H 4-(OC₂H₅)Ph C₂H₅ H

C₂H₅ H Ph R₁ R₂ R₃

CH₃ H Ph

CH₂=CHCH₂ H Ph

C₄H₉ H Ph

Ph-CH₂- H C₃H₇

4 (Cl) -Ph H - CH₂CH=CH₂ i-C₃H₇ H Ph

Ph CH₃ CH₃

Ph H Ph

Ph H n-C₃H₇

Ph H n-C₄H₉

Ph H

2. A compound of Claim 1 wherein R₁ is phenyl.

3. A compound of Claim 2 wherein R₁ is disubstituted in the 2,6-positsons.

4. A compound of Claim 3 wherein R₂ is phenyl.

5. A compound of Claim 4 wherein R₂ is phenyl

disubstituted in the 2,6-positions.

6. A compound of Claim 5 wherein R₃ is hydrogen.

7. A compound of Claim 1 which is:

Methyl[[2,6-bis(1-methylethyl)phenyl amino]sulfonyl]carbamate,

Dodecyl[[2,6-bis(1-methylethyl)phenyl] amino]sulfonyl]carbamate, 2,6-Bis(1,1-dimethylethyl)-4-methoxyphenyl[[(2,2-diphenylethyl)amino]sulfonyl] carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methoxy phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl] carbamate,

2,6-Bis(1,1-dimethylethyl)phenyl- [[(diphenylmethyl)amino]sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]

carbamate,

2,6-Bis(1,1-dimethylethyl)phenyl [[(2,2-diphenylethyl)amino]sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)phenyl

[[bis(phenylmethyl)amino]sulfonyl]carbamate,

2,6-bis(1-methylethyl)phenyl[(diphenylamino)sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[bis(phenylmethyl)amino]sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[(1H- benzimidazol-2-ylamino)sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[2,2- diphenylethyl)amino]sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[[2,6-bis(1- methylethyl)phenyϊ]amino]sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[(diphenylmethyl)amino]sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[(diphenylmethyl)amino]sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[bis(2,6-bis(1-methylethyl)phenyl]amino]- sulfonyl]carbamate, 2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[(2,2-diphenylethyl)amino]sulfonyl]-carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dibutylamino)sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dipentylamino)sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[bis(1-methylethyl)amino]sulfonyl]-carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dihexylamino)sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(hexylamino)sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[methyl(2-phenylethyl)amino]sulfonyl]-carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[bis-3-(dimethylamino)propyl]amino]-sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(methyl octyl amino)sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methyl-[[bis[(tetrahydro-2-furanyl)methyl]amino]-sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dioctylamino)sulfonyl]carbamate,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]-sulfonyl]carbamate, hydrochloride salt,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]-sulfonyl]carbamate, sodium salt,

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dodecylamino)sulfonyl]carbamate, 2,6-Bis(1-methylethyl)phenyl[[bis(1-methylethyl)amino]sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[(1-methylethyl)phenylmethyl)amino]sulfonyl]-carbamate,

2,6-Bis(1-methylethyl)phenyl[(hexylamino)sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[(dioctylamino)sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[[cyclo-hexyl(1-methylethyl)amino]sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[(methyloctylamino)sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl[(dihexylamino)sulfonyl]carbamate,

Dodecyl[[(2,4,6-trimethoxyphenyl)amino]- sulfonyl]carbamate,

2,6-Bis(1-methylethyl)phenyl ester(4- morpholinylsulfonyl)carbamic acid,

2,6-Bis(1-methylethyl)phenyl ester(1- piperidinylsulfonyl)carbamic acid,

2,6-Bis(1-methylethyl)phenyl ester(1- pyrrolidinylsulfonyl)carbamic acid,

2,6-Bis(1-methylethyl)phenyl ester,

monohydrochloride[(4-methyl-1-piperazinyl)- sulfonyl]carbamic acid,

2,6-Bis(1-methylethyl)phenyl ester[(2,3- dihydro-1H-indol-1-yl)sulfonyl]carbamic acid,

2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate monosodium salt,

[1,1:3',1"-Terphenyl]-2'-yl[[[2,6-bis(1- methylethyl)phenyl]amino]sulfonyl]carbamate, and

2,6-Bis(1,1-dimethylethyl)phenyl- [[(diphenylmethyl)amino]sulfonyl]methyl

carbamate.

8. A pharmaceutical composition comprising a

compound of the following general Formula II and an appropriate amount of a pharmaceutically acceptable carrier:

wherein X is oxygen or sulfur;

wherein R₁ is

(a) phenyl which is unsubstituted or is

substituted with from one to three substituents selected from:

phenyl,

alkyl having from one to six carbon atoms and which is straight or branched,

alkoxy having from one to six carbon atoms and which is straight or branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-COOalkyl wherein alkyl has from one to four carbon atoms and which is straight or branched, - (CH₂)_pNR₄R₅ wherein p is zero or one, and each of R₄ and R₅ is hydrogen or a straight or branched alkyl group having one to four carbon atoms;

phenyl,

alkyl having from one to six carbon atoms and which is straight or branched,

alkoxy having from one to six carbon atoms and which is straight or branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-(CH₂)_pNR₄R₅ wherein p, R₄, and R₅ have the meanings defined above;

(c) the group

wherein t is zero or one to four; w is zero or one to four with the proviso that the sum of t and w is not greater than five; R₆ and R₇ are independently selected from hydrogen or alkyl having for one to six carbon atoms,

or when R₆ is hydrogen, R₇ can be selected

from the groups defined for R₈; and R₈ is

phenyl or phenyl substituted with from one

to three substituents selected from straight

or branched alkyl having from one to six

carbon atoms, straight or branched alkoxy

having from one to six carbon atoms,

phenoxy, hydroxy, fluorine, chlorine,

bromine, nitro, trifluoromethyl, -COOH,

COOalkyl wherein alkyl has from one to four

carbon atoms and is straight or branched, or

-(CH₂)_pNR₄R₅ wherein p, R₄ and R₅ have the

meanings defined above;

(d) -(CH₂)_s-Q wherein s is a number of from zero

to three and Q is a 5- or 6-membered

monocyclic or fused bicyclic heterocycle

containing at least one to four nitrogen,

oxygen or sulfur atoms in at least one ring

member; or

(e) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which

is saturated or contains from one to three

double bonds;

wherein each of R₂ and R₃ is

(a) hydrogen;

(b) the group

wherein t, w, R₆, R₇ and R₈ have the

meanings defined above; (c) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;

(e) -(CH₂)_sQ wherein s and Q have the

meanings defined above;

alkyl having from one to six carbon atoms and which is straight or

branched,

alkoxy having from one to six carbon atoms and which is straight or

branched,

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

(g) NR₁R₂ taken, together form a monocyclic heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is

unsubstituted or substituted with one substituent selected from phenyl, or straight or branched alkyl having from one to six carbon atoms; and

pharmaceutically acceptable salts thereof; with the provisos:

(i) when each of R₂ and R₃ is the group

R₇ is hydrogen or alkyl having from one to six carbon atoms;

(ii) at least one of R₁, R₂, and R₃ is phenyl or substituted phenyl;

(iii) both R₂ and R₃ are not hydrogen at the same time;

9. A method for treating hypocholesterolemia and

atherosclerosis in a patient in need thereof which comprises administering an effective amount of a composition of Claim 8 to said patient.

10. A process for preparing a compound of Claim 1

which comprises reacting an alcohol or thiol of the formula R₁XH wherein X is oxygen or sulfur and R₂ has the meaning defined in Claim 1 with chlorosulfonyl isocyanate in an inert organic solvent to give a chlorosulfonyl (thio) carbamate of the formula which is reacted with an amine of the formula HNR₂R₃ wherein R₂ and R₃ have the meanings defined in Claim 1 in an inert organic solvent at ambient temperatures in the presence of an acid scavenger and when a pharmaceutically acceptable salt is desired reacting the thus obtained compound with a pharmaceutically acceptable base or acid.

Also, reacting a base salt with a suitable alkylating agent to give a compound of Claim 1.